h-89 has been researched along with Respiratory-Insufficiency* in 1 studies
1 other study(ies) available for h-89 and Respiratory-Insufficiency
Article | Year |
---|---|
Inhibition of protein kinase A and GIRK channel reverses fentanyl-induced respiratory depression.
Opioid-induced respiratory depression is a major obstacle to improving the clinical management of moderate to severe chronic pain. Opioids inhibit neuronal activity via various pathways, including calcium channels, adenylyl cyclase, and potassium channels. Currently, the underlying molecular pathway of opioid-induced respiratory depression is only partially understood. This study aimed to investigate the mechanisms of opioid-induced respiratory depression in vivo by examining the effects of different pharmacological agents on fentanyl-induced respiratory depression. Respiratory parameters were detected using whole body plethysmography in conscious rats. We show that pre-treatment with the protein kinase A (PKA) inhibitor H89 reversed the fentanyl-related effects on respiratory rate, inspiratory time, and expiratory time. Pre-treatment with the G protein-gated inwardly rectifying potassium (GIRK) channel blocker Tertiapin-Q dose-dependently reversed the fentanyl-related effects on respiratory rate and inspiratory time. A phosphodiesterase 4 (PDE4) inhibitor and cyclic adenosine monophosphate (cAMP) analogs did not affect fentanyl-induced respiratory depression. These findings suggest that PKA and GIRK may be involved in fentanyl-induced respiratory depression and could represent useful therapeutic targets for the treatment of fentanyl-induced ventilatory depression. Topics: Animals; Bee Venoms; Cyclic AMP-Dependent Protein Kinases; Fentanyl; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Isoquinolines; Male; Potassium Channel Blockers; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Respiratory Insufficiency; Sulfonamides | 2018 |